Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Extrapulmonary illness - The Impact of COVID-19 on Nephrology care

Dhwanil Patel, MD\textsuperscript{a}, Tiffany Truong, DO\textsuperscript{b}, Nikhil Shah, MBBS, DNB\textsuperscript{c}, Gates B. Colbert, MD\textsuperscript{d}, Beje Thomas, MD\textsuperscript{e,\textsuperscript{*}}, Juan Carlos Q. Velez, MD\textsuperscript{f}, Edgar V. Lerma, MD\textsuperscript{g}, Swapnil Hiremath, MDMPH\textsuperscript{h}

\textsuperscript{a} New York University School of Medicine, New York, NY, United States
\textsuperscript{b} Division of Nephrology, Keck School of Medicine of USC and Los Angeles County, USC Medical Center, Los Angeles, CA, United States
\textsuperscript{c} Division of Nephrology and Immunology, University of Alberta, Edmonton, Canada
\textsuperscript{d} Texas A&\textbackslash M College of Medicine at Dallas, Dallas, Texas, United States
\textsuperscript{e} MedStar Georgetown Transplant Institute, Washington, DC, United States
\textsuperscript{f} Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA, United States
\textsuperscript{g} University of Illinois at Chicago College of Medicine/Advocate Christ Medical Center, Oak Lawn, IL, United States
\textsuperscript{h} University of Ottawa, Ottawa, Canada

ABSTRACT

Coronavirus disease-2019 (COVID-19) has caused a pandemic that has affected millions of people worldwide. COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and is spread by close contact and by respiratory droplets. It has also impacted different aspects of caring for people with kidney disease, including those with acute kidney injury (AKI), chronic kidney disease (CKD), those requiring kidney replacement therapy (KRT), and those with a kidney transplant. All of these patients are considered high risk. The lessons learned from the COVID-19 pandemic will hopefully serve to protect patients with kidney disease in a similar situation in the future.

© 2020 Elsevier Inc. All rights reserved.
Introduction

Coronavirus disease-2019 (COVID-19) has caused a pandemic that has affected millions of people worldwide. COVID-19 is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and spread by close contact and by respiratory droplets. Though SARS-CoV-2 is considered a respiratory virus with the most fearful complication being respiratory failure, it does affect multiple organ systems including the kidneys. In this article we review how COVID-19 involves the kidney, causing acute kidney injury (AKI), and how it affects patients on kidney replacement therapy (KRT) with hemodialysis (HD) and peritoneal dialysis (PD), and those with a kidney transplant. The information in this review reflects the understanding as of the date of writing, which is still evolving, and regular updates are being posted on the NephJC blog (www.nephjc.com/covid19).

Acute kidney injury

Early studies coming primarily from China reported a relatively low incidence of AKI in COVID-19 (CoV-AKI), ranging between 3 and 9% depending on the population studied. Subsequently, in the initial report from the United States of America (USA) in individuals with COVID-19 admitted to the intensive care unit (ICU), 19% (4/21 patients) acquired AKI. However, more recent and larger reports (see Table 1) from the US and United Kingdom described a higher incidence of CoV-AKI, of 28 to 43% among hospitalized patients and 61 to 76% among those who are critically ill. Furthermore, rates of KRT have ranged between 15 and 20% of patients with CoV-AKI, and even higher rates of 34 to 73% for those admitted to the ICU. CoV-AKI is also associated with a higher mortality rate.

CoV-AKI is associated with proteinuria and hematuria, which is not uncommon with acute tubular injury (ATI), however the degree of each is not known as there has been sparse reporting of quantitative data. A granular description of the AKI phenotype suggests that the predominant etiology of CoV-AKI, which is largely associated with hemodynamic instability, is indeed acute tubular injury (ATI). A smaller subset of patients presented with features suggestive of toxic ATI from rhabdomyolysis, whereas pre-renal azotemia represented only 9% of the causes. An ancillary report from the same study from Mohamed et al. from New Orleans, USA reported that abundant granular and waxy casts indicative of ATI were the predominant finding on urine microscopy. In agreement with those clinical observations, a postmortem case series by Su et al. reported findings of ATI on autopsies of 9 patients who died from COVID-19. Thus far, there is a paucity of data from pre-mortem tissue diagnosis. From the same group, 3 patients, all African American (AA), out of 161 patients with CoV-AKI with findings suggestive of glomerular disease underwent kidney biopsy which revealed collapsing glomerulopathy in each biopsy. This is in line with emerging reports of collapsing glomerulopathy in AA individuals who are carriers of the Apolipoprotein L1 (APOL1) high risk genotype and acquire COVID-19. Thus, collapsing glomerulopathy should be suspected in AA individuals presenting with AKI and new onset nephrotic range proteinuria, where the COVID-19 potentially serves as a second hit. Nevertheless, this entity does not account for the bulk of the AKI cases. Lastly, even thrombotic microangiopathy has been reported, which is probably rare, but might be underreported given the paucity of kidney biopsy data.

Despite the notion that ischemic ATI is the predominant etiology of AKI in patients with COVID-19, AKI without a clear cause has been observed. As a result, speculation regarding direct viral entrance of the SARS-CoV-2 coronavirus into the kidneys has arisen. The speculation has been driven by the fact that the membrane-bound peptidase angiotensin converting enzyme 2 (ACE2) acts as a receptor for SARS-CoV-2 and is expressed in the kidney tissue, both in tubules and glomerular podocytes. The aforementioned postmortem study by Su et al. reported en-
hanced expression of ACE2 in parietal epithelial cells and presence of viral nucleoproteins in tubular cells. Another report of viral detection in kidney tissue has added ammunition to that contention\textsuperscript{20}. However, there is still no definite demonstration that viral presence in the kidneys is a causative phenomenon in CoV-AKI.

With the sudden surge in COVID-19 cases in the USA, healthcare resources were quickly saturated in states such as New York, California, New Jersey, and Louisiana. There was national coverage in the media regarding the shortage of ventilators due to respiratory failure in COVID-19. However, there was little mention of the stretched dialysis resources. Among the options used as a contingency include shortening the time on dialysis, even for continuous kidney replacement therapy (KRT), by making it less continuous, decreasing dialysis frequency, and decreasing the need for dialysis, by being more judicious in fluid resuscitation, and using potassium binding exchange resins\textsuperscript{21-22}. Centers throughout the world with similar issues reported initiation of an urgent peritoneal dialysis (PD) program, which is unprecedented in the Western Hemisphere for AKI to be able to provide KRT to patients (further discussed in the following section on PD).

**Kidney replacement therapy: chronic hemodialysis**

Patients on long term KRT are on either hemodialysis (HD) or peritoneal dialysis (PD) on a regular basis. These patients on long term dialysis have chronic health conditions and im-
munomodulating factors that make them especially vulnerable to COVID-19. This increased vulnerability to nosocomial and community spread infections requires several steps by caregivers and healthcare systems to continue dialysis treatments in a safe environment.

We will first discuss long term KRT in terms of HD then PD. Patients on chronic HD routinely receive three treatments weekly at an outpatient dialysis unit. During these dialysis sessions, the patients are in continual contact and close proximity with other patients and caregivers. Thus, patients on HD cannot self-isolate, and have repeated and ongoing potential exposure. Dialysis centers implemented strategies to keep the staff and patients from contracting COVID-19 through the known mechanisms of spread\textsuperscript{23}. These strategies included screening at the entrance of the dialysis facilities with a health and symptom questionnaire, and a rapid temperature check for fever\textsuperscript{24}. Patients with symptoms or an elevated temperature were advised to not enter the facility and go for COVID-19 testing. Strategies used to avoid nosocomial spread including co-horting patients with suspected or confirmed COVID in separate units, the last shift of dialysis, and/or physically isolate them as much as possible. All patients and staff were encouraged to wear Centers for Disease Control (CDC) endorsed personal protective equipment (PPE) including facial masks at a minimum, with staff wearing gowns and gloves\textsuperscript{25}.

If a patient who is on dialysis therapy contracted COVID-19, the disease course and severity has ranged widely. As with AKI, the initial data from China has been overshadowed by more grim numbers from larger studies. A small preprint study from a Chinese dialysis unit suggested the course may be milder in dialysis patients compared to other patient cohorts\textsuperscript{26-27}. Of the 230 patients at this one unit, only 37 developed COVID-19 and 27 of those patients were asymptomatic. Subsequent data is much worse, with mortality rates in the range of 20 - 30% (Table 2).

Dialysis access patency is fundamental to achieving life saving treatments. At the outbreak of the pandemic in the United States in March 2020, all non-emergent surgeries were encouraged to be delayed to preserve healthcare resources. However, patients with dialysis access that had clotting or non-function status cannot wait days and weeks to re-establish patency, since lack of dialysis access means no dialysis. For these patients, vascular access is a lifeline. Hence, the American Society of Diagnostic and Interventional Nephrology (ASDIN) and Vascular Access Society of the Americas (VASA) issued a joint statement urging healthcare centers and hospitals to prioritize dialysis access procedures as life threatening necessary surgeries\textsuperscript{28}.

### Peritoneal dialysis

The COVID-19 pandemic brought the benefits of home dialysis with peritoneal dialysis (PD) into sharp focus. The ability to dialyze and stay quarantined in the patient’s own home is ideal compared to travelling three times a week to an in-center dialysis unit. However, the other aspect of PD that had an important role was the use of urgent start PD (see Fig. 1).

The ability to initiate urgent PD has been crucial since during the COVID-19 pandemic many health care systems have been stretched thin including to the point that there was a shortage of continuous KRT machines and supplies\textsuperscript{21-29}. In some centers, even the availability of HD to accommodate AKI patients needing dialysis became a problem. PD provides a viable option in

| Study | Setting | Incidence of COVID-19 | Mortality rate with COVID-19 |
|-------|---------|-----------------------|-----------------------------|
| UK Renal Registry | UK | 2211 cases (-4.9%) | 498 (22.5%) |
| ERA-EDTA registry | European registry | 278 cases | 20% |
| Xiong et al. | 65 centres in Wuhan, China | 154 cases of 7154 (2.2%) | 41 (26.6%) |
| Alberici et al. | Four dialysis centers of the Brescia Renal COVID Task Force, Lombardy, Italy | 94 cases of 643 (15%) | 24 (25.5%) |

UK: United Kingdom; ERA-EDTA: European Renal Association and European Dialysis and Transplantation Association.

Table 2: Incidence and outcomes with COVID-19 in chronic hemodialysis populations.
PD Prescription for Acute Kidney Injury - Sample Protocol

Table 3
Advantages and Disadvantages in urgent start PD. ICU: intensive care unit; IR: interventional radiology.

| Peritoneal Dialysis In Acute Kidney Injury in ICU during COVID19 Pandemic | Disadvantages |
|---|---|
| Relatively simple to insert bedside PD catheters for ICU patients by IR/Surgeons or Interventional Nephrologists | Precise ultrafiltration is slightly more difficult |
| Avoid vascular access and need for anticoagulation | May need innovative exit sites and dialysis scheduling to accommodate prone ventilation. |
| Intra-abdominal pressure may be affected by prone positioning |

these situations. Acute PD protocols are clearly outlined in the International Society for Peritoneal Dialysis (ISPD) guidelines. Specific concerns relate to arranging the insertion of these catheters (typically surgeons, or interventional radiologists or nephrologists), and the specific protocols that need to be used to ensure metabolic and volume control which can be challenging in the critically ill patient.

The majority of elective surgeries were initially canceled during the COVID-19 crisis, however many institutes and professional organizations including the American Society of Nephrology classified PD catheter insertion as an essential service. Avoiding the start of PD would result in a greater pressure on HD services, which are under stress, as discussed before. Even for chronic kidney disease (CKD) patients in need of urgent dialysis (e.g. in cases where the kidney function has worsened rapidly, or were previously not recognized to have CKD ‘crash starts’) an urgent PD start can be considered. Urgent PD can mostly be started within 24–48 h of catheter insertion, using low volume exchanges in the supine position, especially using cyclers. Peritoneal dialysis in a patient with acute respiratory distress syndrome (ARDS) requiring prone ventilation presents several challenges. PD in prone patients has been previously described, one recent protocol provides some suggestions on managing patients with PD in prone position. PD catheter exit site could be placed more laterally than usual to accommodate the prone position. In addition, there is some anecdotal experience in using pillows to prop up the chest and pelvis to reduce the intra-abdominal pressure in a prone patient on PD. We have listed the possible advantages and disadvantages of PD in Table 3.
With regards to home dialysis in general and PD specifically, routine outpatient follow up is adapted to keep patients at home and care is provided virtually by various telemedicine platforms that have come to prominence during the pandemic. Timely CMS waivers provided flexibility to accommodate virtual visits for home dialysis. Many programs have adapted to this new reality and have used telehealth platforms like Zoom to provide patient care, assessment and education for home dialysis.

PD depends heavily on supplies provided by the companies that make and supply the consumables required for PD. In addition to the PD bags and cyclers, PD patients require large daily quantities of masks and hand sanitizer supplies to perform the procedure using aseptic precautions. With the broad disruption of supply chains during the pandemic, it is advisable to keep a minimum of 2 weeks of rolling stock at hand to ensure safe PD.

**COVID-19 and kidney transplantation**

The COVID-19 pandemic has adversely affected multiple aspects of kidney transplantation. Kidney transplant rates dropped (see Fig. 2) at the onset of the pandemic with the suspension of 72% of living donor programs and limitations on the operations of 84% of deceased donor programs. This decline ensued despite the Centers for Medicare and Medicaid Services (CMS) identifying kidney transplantation as a Tier 3b procedure that should not be postponed if pos-
sible, reflecting concerns about risk of COVID-19 transmission, limited healthcare resources, and limited knowledge of this novel disease. As all regions have seen some recovery in transplantation rates in May of 2020, transplant programs continue to grapple with various issues of transplant care during the COVID-19 pandemic.

Initially, transplantation evaluations decreased during the early period of COVID-19. This occurred due to drops in actual transplantation rates, as well as concern for increasing exposure to COVID-19 during evaluations. In response, the increased use of telemedicine pre- and post-transplant has allowed patients to continue their evaluation while minimizing risk of exposure to COVID-19. The Organ Procurement and Transplant Network (OPTN) also recognized the decreased access to transplantation during the pandemic. They have allowed for a program to apply for a waiting time modification that back dates listing times to the start of the pandemic. Additionally, concerns for donor-derived infection have led to the implementation of routine screening of living and deceased donors for COVID-19 with test results available within hours. Presently, if a donor tests positive for COVID-19 they likely will not be used though this could change in the future.

Kidney transplant patients are considered a high risk patient population due to immunosuppression and their increased risk of infection. Risk factors associated with increased morbidity and mortality with COVID-19 infection include increased age, obesity, and history of chronic heart, lung, or kidney disease. All these risk factors are commonly found in patients with CKD and hence in kidney transplant patients.

Kidney transplant recipients infected with COVID-19 appear to have similar clinical presentations as the general population, though morbidity, including need for mechanical ventilation, and mortality vary among reports. In a case series of 15 kidney transplant recipients hospitalized with COVID-19 in New York, patients most often presented with symptoms of fever and/or cough, chest x-ray findings of bilateral infiltrates, and other elevated inflammatory markers. Mechanical ventilation was required in about 30% of these patients. In another case series of 35 kidney transplant recipients with COVID-19 from both the inpatient and outpatient settings in New York, 39% of patients needed mechanical ventilation, 21% needed KRT, and the mortality rate was 28% at 3 weeks, significantly higher than the general population in the United States whose mortality rate is reported to be 1 to 5%. This contrasts with a large, international European study, which reported the mortality rate in patients with kidney transplant was 18%, comparable to the 20% mortality rate of patients on dialysis. For those transplant recipients with mild disease, few comorbidities, and ability to communicate closely with their transplant team, outpatient management may be considered.

Management of immunosuppression for patients with kidney transplant and COVID-19 primarily consists of discontinuation of the anti-metabolite, usually mycophenolate mofetil or mycophenolate acid, and, with severe infection, also holding the calcineurin inhibitor. Calcineurin inhibitors in vitro have been shown to inhibit the replication of coronaviruses, though it is unclear if this effect will occur in vivo. Corticosteroids have unclear benefit at this time as they have been associated with a longer duration of viral shedding and higher viral loads, but have also been explored as an experimental therapy with variable success.

A wide range of experimental therapies (see Table 3) have been used, including hydroxychloroquine, azithromycin, tocilizumab, and remdesivir. Careful consideration of drug dosing and interactions need to be always considered in the kidney transplant patient. Table 4 shows potential treatments and interactions when considering COVID-19 treatments.

Telehealth

We have already discussed the rapid adaptation of telehealth in kidney transplantation. However, telehealth or telenephrology was also adapted during the pandemic for use for CKD patients in the outpatient clinic setting. Recently a review by Koraishy et al. discussed telenephrology in detail. Although telehealth carries limitations in the ability to thoroughly assess patients, nephrology is well-suited for it due to its nature of being primarily a “numerical spe-
Table 4
List of potential COVID-19 treatments with drug interactions with commonly used immunosuppressants (from Nephjc http://www.nephjc.com/news/covidtx).

| Drug | Dose reported in COVID-19 trials | Dose adjustment in CKD? | Drug Interactions in Transplant | Other considerations |
|------|----------------------------------|-------------------------|--------------------------------|----------------------|
| Remdesivir | 200 mg x 1 then 100 mg daily | ? None¹ | None reported | CrCl < 30 exclusion in most trials¹ |
| Lopinavir/Ritonavir (Kaletra) | 400 mg / 100 mg twice daily | None | ↑Cyclosporine, tacrolimus levels ↑↑ Sirolimus levels ? Effect on mycophenolate | Both highly protein bound |
| Chloroquine/ Hydroxychloroquine (Plaquenil) | CQ: 500 – 1000 mg a day (or 10 mg/kg) HCQ: 400 mg x1 then 200 mg two or three times a day | None³ | ↑Cyclosporine, tacrolimus, sirolimus levels | – 50–70% protein bound; high volume of distribution |
| Darunavir / Ritonavir (Prezista / Norvir) | 800 mg / 100 mg daily | None | ↑Cyclosporine, tacrolimus levels ↑↑ Sirolimus levels ? Effect on mycophenolate | Both highly protein bound |
| Favipiravir | 1200 mg twice daily for 2 days then 600 mg 2–3 times a day | ?Yes | None reported | ~50% protein bound |
| Tocilizumab | 8 mg/kg (up to max 800 mg) | None | ↓Cyclosporine, tacrolimus, sirolimus levels | |
| Colchicine | 0.5 mg twice daily² | Yes⁴ | ↑Cyclosporine, tacrolimus levels ? Sirolimus levels Avoid with azathioprine | High volume of distribution; ~40% protein bound |

Names in italics refer to brand names.

¹ This is a common reported exclusion, due to the potential toxicity of the excipient.
² Dose in gout is usually 0.6 mg, this dose is reported for the COLCORONA trial.
³ These drugs do have some clearance by kidneys, so accumulation with occur with chronic dosing, not relevant in the COVID-19 setting.
⁴ CrCl < 30 an exclusion in the COLCORONA trial:CQ: chloroquine; HCQ: hydroxychloroquine; CrCl: creatinine clearance.

CKD is known as a “silent killer” highlighting the fact that most CKD patients are not typically symptomatic until the late stages of CKD. Periodical assessment of changes if kidney function, degree of proteinuria, anemia etc., is fully accomplished with lab review and addresses the most relevant aspects of CKD care. Patients are required to undergo blood draws at a lab facility and though this is an exposure risk many private and in-hospital clinics have taken precautions to limit exposure. In regard to physical findings, edema, the most salient in this patient population, can be assessed with the use of video or photography. Thus, telehealth proved to be a viable tool to manage outpatient CKD clinics during the pandemic.

Conclusion

COVID-19 has had a tremendous effect on the world and causes very high morbidity and mortality. In the critically ill patient, COVID-19 also causes AKI, with 10 to 30% needing KRT.
We have discussed how in the dialysis population there had to be changes to protect patients and staff. That the stress on the healthcare systems caused at times a lack of availability of certain kidney replacement modalities and that the innovative use of urgent PD became a more widely used option. Finally, the effects on kidney transplantation included a drop in transplant evaluations and transplant surgeries. We noted that while transplant patients are considered high risk for infection with COVID-19, their presentations have been similar to the general population, with higher mortality rates comparable to that of patients on dialysis. Much of this information, especially the role of specific therapeutic management, is still evolving as trials are ongoing. As we move forward with preventative measures, it is important to remember the unique characteristics of patients with chronic kidney disease, end stage kidney disease, or those with a transplant and how they might be affected by a future situation similar to the COVID-19 epidemic.

References

1. Centers for disease control and prevention. What you should know about COVID-19 to protect yourself and others. Accessed June 12, 2020. https://www.cdc.gov/coronavirus/2019-ncov/downloads/2019-ncov-factsheet.pdf
2. Naicker S, Yang C-W, Hwang S-J, Liu B-C, Chen J-H, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824–828. doi:10.1016/j.kint.2020.03.001.
3. Wang D, Hu B, Hu C, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi:10.1001/jama.2020.1585.
4. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5.
5. Arentz M, Yim E, Klaflf L, et al. Characteristics and outcomes of 21 critically ill Patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612. doi:10.1001/jama.2020.4326.
6. Mohamed MM, Lukitsch I, Torres-Ortiz AE, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney360. 2020 Published online May 13,. doi:10.34067/KID.000265202010.34067/KID.0002652020.
7. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 Published online May3085523820305329. doi:10.1016/j.kint.2020.05.006.
8. Chan L, Chaudhary K, Saha A, et al. Acute kidney injury in hospitalized patients with COVID-19. Nephrology. 2020. doi:10.1111/nep.13094.
9. ICNARC – Reports. Accessed June 19, 2020. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports
10. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(11):1708–1720. doi:10.1056/NEJMoa2002032.
11. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838. doi:10.1016/j.kint.2020.03.005.
12. Hernandez-Arroyo CF, Varghese V, Mohamed M.M.B., Velez J.C.Q. Urinary sediment microscopy in acute kidney injury associated with COVID-19. Kidney360. Published online June 2, 2020. 10.34067/KID.0003352020.
13. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 Published online April508552382030690. doi:10.1016/j.kint.2020.04.003.
14. Larsen CP, Bourne TD, Wilson JD, Saqqa O, Sharshir MA. Collapsing glomerulopathy in a patient with COVID-19. Kidney Int Rep. 2020;5(6):935–939. doi:10.1016/j.ekir.2020.04.002.
15. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and collapsing glomerulopathy associated with COVID-19 and APOL1 high-risk genotype. J Am Soc Nephrol. 2020;31(6) ASN.2020050558. doi:10.16181/ASN.2020050558.
16. Jhaveri KD, Meir LR, Flores Chang BS, et al. Thrombotic microangiopathy in a patient with COVID-19. Kidney Int. 2020 Published online June 7. doi:10.1016/j.kint.2020.05.025.
17. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224. doi:10.1038/s41586-020-2179-y.
18. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Battle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17(11):3067–3075. doi:10.1615/1050-9231.E3043.
19. Velez J.C.Q, Bland AM, Arthur JM, Raymond JR, Janech MG. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol-Ren Physiol. 2007;293(1):F398–F407. doi:10.1152/ajprenal.00050.2007.
20. Puelles VC, Lütgehahm M, Lindenmeyr MT, et al. N Engl J Med. Multiorgan and Renal Tropism of SARS-CoV-2; 2020 Published online May 13.
21. Goldfarb DS, Benstein JA, Zhdanova O, et al. Impacting shortages of kidney replacement therapy for COVID-19 patients. Clin J Am Soc Nephrol. 2020;15(6):880–882. doi:10.2215/CJN.05180420.
22. Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020;20(0)(8):1–8. doi:10.1080/17512433.2020.1774363.
23. American Society of Nephrology. Information for screening and management of COVID-19 in the outpatient dialysis facility. Published March 13, 2020. Accessed June 12, 2020. https://www.asn-online.org/g/blast/files/DIALYSIS_COVID_2019_Update_03.13.2020_FINAL.pdf
53. Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm. J Am Soc Nephrol. 2020;31(6):1145–1146. doi:10.1681/ASN.2020020348.
54. Ogimi C, Greninger AL, Waghmare AA, et al. Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: risk factors and viral genome evolution. J Infect Dis. 2017;216(2):203–209. doi:10.1093/infdis/jix264.
55. Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ. Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. J Virol. 2008;82(9):4420–4428. doi:10.1128/JVI.02190-07.
56. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–309. doi:10.1016/j.jcv.2004.07.006.
57. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473–475. doi:10.1016/S0140-6736(20)30317-2.
58. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–684. doi:10.1016/S0140-6736(20)30361-5.
59. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276. doi:10.1016/S2213-2600(19)30417-5.
60. University of Oxford. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Published June 15, 2020. https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf
61. University of Liverpool. Interactions with experimental COVID-19 immune therapies. Published June 4, 2020. Accessed June 15, 2020. https://www.covid19-druginteractions.org/prescribing-resources
62. University of Liverpool. Interactions with experimental COVID-19 viral therapies. Published June 4, 2020. Accessed June 15, 2020. https://www.covid19-druginteractions.org/prescribing-resources
63. Koraishy FM, Rohatgi R. Telenephrology: an emerging platform for delivering renal health care. Am J Kidney Dis. 2020;0(0). doi:10.1053/j.ajkd.2020.02.442.